Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial

NCT06438627 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

164

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: TPC combined with Apatinib and Camrelizumab
DRUG: GP Combined With Camrelizumab

Sponsor

XIANG YANQUN